🔎 Trials Near Me

ホーム › 腎臓がん(腎細胞がん) › アーカンソー州

アーカンソー州における腎臓がん(腎細胞がん)の臨床試験

アーカンソー州内の拠点で、腎臓がん(腎細胞がん)に関する6件の研究が参加者を募集しています。

アーカンソー州内の都市

公式研究テキスト(英語)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Hospital Fort Smith, Fort Smith
  • CARTI Cancer Center, Little Rock
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  • University of Arkansas for Medical Sciences, Little Rock
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05327686

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Highlands Oncology Group, Fayetteville
  • Highlands Oncology Group, Rogers
  • Highlands Oncology Group, PA, Springdale
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07227415

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
  • University of Arkansas for Medical Sciences, Little Rock
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06661720

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

  • Highlands Oncology Group - Fayetteville, Fayetteville
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
  • Highlands Oncology Group - Rogers, Rogers
  • 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/11更新 · NCT07383441

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • Mercy Hospital Fort Smith, Fort Smith
被験者募集中第3相
18歳以上 · 全性別 · 2025/09/09更新 · NCT04510597

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。